Table 1.
Clinico-demographic data of participants.
| Total n = 158 | Nr. of studied subjects | Sex (M/F) | Age at PD onset ± SD (years) | Age at sampling ± SD (years) | Time from baseline ± SD (years) | Mean LEDD ± SD (mg) | Mean MDS UPDRS-III ± SD (Nr. of available from total) | Nr. of pheno-converted subjects |
|---|---|---|---|---|---|---|---|---|
| Controls | 40 | 28/12 | – | 65.48 ± 11.69 | – | – | – | – |
| L2NMC DaT- | 20 | 8/12 | – | 52.30 ± 10.12 | – | – | 0.39 ± 0.61 (n = 18/20) | – |
| Time point 2 | 18 | 6/12 | – | 56.78 ± 11.60 | 4.32 ± 1.68 | – | 1.72 ± 1.79 (n = 16/18) | 0 |
| Time point 3 | 16 | 7/9 | – | 59.50 ± 11.40 | 7.79 ± 2.22 | – | 2.33 ± 2.23 (n = 12/16) | 0 |
| L2NMC DaT+ | 20 | 12/8 | – | 60.50 ± 14.49 | – | – | 3.10 ± 5.22 (n = 20/20) | – |
| Time point 2 | 16 | 9/7 | – | 61.63 ± 13.26 | 5.02 ± 1.50 | – | 6.34 ± 10.26 (n = 16/16) | 3 |
| Time point 3 | 13 | 8/5 | – | 63.85 ± 11.63 | 9.12 ± 1.68 | – | 5.19 ± 5.64 (n = 8/13) | 4 |
| L2PD | 20 | 12/8 | 58 ± 13.14 | 65 ± 10.90 | – | 802.47 ± 810.02 | 22.00 ± 13.10 (n = 17/20) | – |
| iPD | 19 | 12/7 | 56.16 ± 13.01 | 63.53 ± 11.77 | – | 420.13 ± 391.46 | 25.00 ± 16.37 (n = 8/19) | – |
| L2PD 2nd cohort | 19 | 8/11 | 53.47 ± 10.79 | 64.47 ± 11.34 | – | 708.68 ± 469.64 | 28.05 ± 13.87 (n = 19/19) | – |
| Controls 2nd cohort | 20 | 8/12 | – | 63.65 ± 10.75 | – | – | – | – |
UPDRS-III scaling is provided as a mean ± standard deviation (SD) with the number of subjects with available data specified in brackets.
DaT DaT-SPECT imaging, L2NMC LRRK2 non-manifesting carriers, L2PD LRRK2-associated PD patients, iPD idiopathic PD patients, sex: M males, F females, LEDD levodopa equivalent daily dose, MDS UPDRS-III Unified Parkinson’s Disease Rating Scale scoring of the Movement Disorders Society.